You are here: Industry Insights > ProBioGen

News List

City of Hope Takes a Commercial Product License to Use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform b3cnewswire
June 10, 2021
ProBioGen AG has announced a commercial product license agreement with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases
ProBioGen and Minapharm Pharmaceuticals incorporate MiGenTra GmbH - A Healthcare Transforming Medicines Company prnasia
May 27, 2021
ProBioGen and Minapharm Pharmaceuticals announce the incorporation of ProBioGen's subsidiary "MiGenTra" with headquarters in Berlin and access to a site in Cairo, which will house its principal manufacturing plant.
Asher Bio, ProBioGen Ink Development, Mfg. Agreement contractpharma
April 27, 2021
ProBioGen to provide cell line development, process development and GMP manufacturing at 1000 L bioreactor scale of Asher's lead immuno-oncology candidate.
RDIF and Minapharm agree to produce over 40 million doses of the Sputnik V vaccine in Egypt prnasia
April 22, 2021
The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), Egypt's Minapharm, the regional leader in recombinant DNA technology, and its Berlin-based subsidiary, ProBioGen AG, announce the agreement to produce over 40 million doses per ...
ProBioGen, Nobelpharma Enter Mfg. Agreement for Vax Project contractpharma
March 25, 2021
ProBioGen AG signed a service agreement for Nobelpharma’s vaccine project leveraging ProBioGen’s vaccine development platform consisting of its AGE1.CR.pIX suspension cell line and its high performance cell culture medium, for the propagation of ...
AbbVie Licenses ProBioGen’s GlymaxX Technology contractpharma
January 26, 2021
ProBioGen has signed a commercial license agreement with AbbVie to apply ProBioGen's GlymaxX technology to boost the antibody-dependent cell-mediated cytotoxicity (ADCC).
Asahi Kasei Pharma Contracts ProBioGen contractpharma
November 20, 2020
ProBioGen AG has closed a master service agreement with Asahi Kasei Pharma. As a CDMO in high-tier cell line development till large scale GMP manufacturing, ProBioGen will use its proprietary technologies, like the CHO.
ImmunOs Uses ProBioGen’s Pathway Modulator Technology contractpharma
October 29, 2020
DirectedLuck transposase technology will be used to increase protein yield of selected candidates in their pipeline of complex recombinant proteins.
ProBioGen, Heidelberg Pharma Ink ATAC Agreement contractpharma
October 23, 2020
ProBioGen is conducting cell line development, process development and GMP manufacturing of the mAb intermediates of Heidelberg’s ATAC molecules for cancer.
ProBioGen Appoints CEO contractpharma
May 04, 2020
ProBioGen AG, a Berlin-based contract development and manufacturing organization (CDMO) for developing and manufacturing complex therapeutic glycoproteins, has appointed Dr. Lutz Hilbrich as chief executive officer, effective June 1, 2020.

Previous page 1 2 3 4 5 6 Next page